Sage Journals: Discover world-class research

Abstract

This report describes the biologic evaluations of [^99mTc(HYNIC-3P-RGD₂)(tricine)(TPPTS)] (^99mTc-3P-RGD₂: 6-hydrazinonicotinyl; 3P-RGD₂ = PEG₄-E[PEG₄-c(RGDfK)]₂; PEG₄ = 15-amino-4,7,10,13-tetraoxapentadecanoic acid; and TPPTS = trisodium triphenylpho-sphine-3,3′,3“-trisulfonate), [^99mTc(HYNIC-3G-RGD₂)(tricine)(TPPTS)] (^99mTc-3G-RGD₂: 3G-RGD₂ = G₃-E[G₃-c(RGDfK)]₂ and G₃ = Gly-Gly-Gly), and ^99mTcO(MAG₂−3G-RGD₂) (MAG₂ = mercaptoacetylglycylglycyl) as radiotracers for noninvasive imaging of tumor integrin α_vβ₃ expression in five xenografted tumor-bearing models. Biodistribution and imaging studies were performed in athymic nude mice bearing U87MG, MDA-MB-435, A549, HT29, or PC-3 tumor xenografts. Immunochemistry was performed using the cultured primary tumor cells and xenografted tumor tissues. It was found that the radiotracer tumor uptake followed the trend U87MG > MDA-MB-435 ≈ HT29 ≈ A549 > PC-3. The total integrin β₃ expression levels followed the general trend: U87MG > MDA-MB-435 ≈ A549~HT29 > PC-3. There is a linear relationship between the radiotracer injected dose per gram tumor uptake and the total integrin β₃ expression levels. On the basis of these, it was concluded that radiotracer tumor uptake is contributed by integrin α_Vβ₃ expressed on tumor cells and activated endothelial cells of the tumor neovasculature. ^99mTc-3P-RGD₂ has the capability to monitor integrin α_vβ₃ expression in a noninvasive fashion.

RADIOLABELED CYCLIC RGD (ARGININE-GLYCINE-ASPARTIC ACID) PEPTIDES represent a new class of radiotracers that target the integrin α_vβ₃ expressed on tumor cells and activated endothelial cells of the tumor neovasculature.^1–9 Noninvasive measurement of integrin α_vβ₃ expression is highly desirable for patient selection before antiangiogenic treatment and for more effective monitoring of therapeutic efficacy in integrin α_vβ₃–positive cancer patients.^10–12 Over the last several years, many multimeric cyclic RGD peptides, such as E[c(RGDfK)]₂ (RGD₂) and E{E[c(RGDfK)]₂}₂ (RGD₄), have been used to maximize integrin α_vβ₃ binding affinity and radiotracer tumor uptake.^13–24 It has been demonstrated that radiolabeled (^99mTc, ¹⁸F, ⁶⁴Cu, ⁶⁸Ga, and ¹¹¹In) multimeric cyclic RGD peptides have better tumor-targeting capability, as evidenced by their higher tumor uptake, with longer tumor retention time than their monomeric counterparts.

Recently, we reported a series of ^99mTc-labeled cyclic RGD dimers, examples of which are shown in Figure 1 (^99mTc-3P-RGD₂: 3P-RGD₂ = PEG₄-E[PEG₄-c(RGDfK)]₂, PEG₄ = 15-amino-4,7,10,13-tetraoxa-pentadecanoic acid; and ^99mTc-3G-RGD₂, 3G-RGD₂ = G₃-E[G₃-c(RGDfK)]₂, G₃ = Gly-Gly-Gly), as new radiotracers for tumor imaging in athymic nude mice bearing U87MG glioma and MDA-MB-435 breast cancer xenografts.^25,26 The integrin α_vβ₃ binding assay showed that 3P-RGD₂ and 3G-RGD₂ are bivalent, as evidenced by their higher binding affinity than that of RGD₂. It has been clearly demonstrated that the addition of PEG₄ and G₃ linkers is responsible for the improved tumor uptake of ^99mTc-3P-RGD₂ and ^99mTc-3G-RGD₂ owing to their bivalency in binding to integrin α_vβ₃ and their faster clearance kinetics from the liver and kidneys. Similar results were obtained for other radiotracers,^27–31 such as ^99mTcO(MAG₂−3G-RGD₂) (see Figure 1: MAG₂ = mercaptoacetylglycylglycyl),^{30 99m}TcO(MAG₂−3P-RGD₂),³¹ ⁶⁴Cu(DOTA-3P-RGD₂) (DOTA = 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetracetic acid), and ⁶⁴Cu(DOTA-3G-RGD₂).²⁷ ^99mTc-3P-RGD₂ has been selected as a candidate for clinical evaluations because of its high tumor uptake, long tumor retention time, and high metabolic stability in athymic nude mice bearing U87MG glioma and MDA-MB-435 breast cancer xenografts.³²

Figure 1.

Cyclic RGD peptide dimers and their ^99mTc complexes.

It is well established that integrin α_vβ₃ is highly expressed on tumor cells and activated endothelial cells of the tumor neovasculature.^33–39 It is also known that integrin α_vβ₃ expression is quite heterogeneous among different tumor types.⁴⁰ It has been demonstrated that radiolabeled cyclic RGD peptides are able to bind to integrin α_vβ₃ for noninvasive imaging of solid tumors in cancer patients.^41–45 The ability to visualize integrin α_vβ₃ expression provides new opportunities to characterize tumor angiogenesis noninvasively, to select appropriate patients for antiangiogenic treatment, and to monitor the therapeutic efficacy of antiangiogenic drugs in cancer patients. Although many radiolabeled cyclic RGD peptides have been developed for integrin α_vβ₃ imaging, reports on the correlation between integrin α_vβ₃ expression levels and radiotracer tumor uptake are relatively rare. Haubner and colleagues first investigated the relationship between tumor uptake of [¹⁸F]galacto-RGD and integrin α_vβ₃ expression levels in several subcutaneous tumor-bearing models.⁴¹ The tumor to muscle ratios obtained from micro–positron emission tomographic (PET) images and direct tissue sampling were compared with relative integrin α_v expression measured by Western blot analysis. In clinical studies, Beer and colleagues found that there was a significant correlation between the standard uptake values (SUVs) of [¹⁸F]galacto-RGD with microvessel density and integrin α_vβ₃ intensity from immunohistochemical staining studies.⁴²,⁴⁵ Zhang and colleagues also explored the relationship between the radiotracer's SUVs and the integrin expression in multiple tumor models.⁴⁶ Although a good correlation was reported, the integrin α_vβ₃ expressed on the neovasculature was completely ignored.

In this study, we evaluated ^99mTc-3P-RGD₂ for its ability to monitor integrin α_vβ₃ expression levels in five different xenografted tumor-bearing animal models (U87MG glioma, MDA-MB-435 breast cancer, A549 lung cancer, HT29 colon cancer, and PC-3 prostate cancer). We were interested in these five human tumor cell lines because they have different levels of integrin α_vβ₃ expression.⁴⁶ For comparison purposes, ^99mTc-3G-RGD₂ and ^99mTcO(MAG₂−3G-RGD₂) were evaluated in the same animal models. The main objective of this study was to establish the relationship between tumor uptake and integrin α_vβ₃ expression levels regardless of the radiotracer's identity and to characterize the integrin α_vβ₃ expression levels on both tumor cells and activated endothelial cells of tumor neovasculature.

Experimental

Materials and Methods

Chemicals were purchased from Sigma-Aldrich (St. Louis, MO). ^99mTc-3P-RGD₂, ^99mTc-3G-RGD₂, and ^99mTcO (MAG₂−3G-RGD₂) were prepared according to methods described in the literature.^25,26,28 Na^99mTcO₄ was obtained from a commercial DuPont Pharma ⁹⁹Mo/^99mTc generator (North Billerica, MA). The radio-high-performance liquid chromatography (HPLC) method used the LabAlliance (State College, PA) HPLC system equipped with a β-ram IN-US detector and Zorbax C₁₈ column (Agilent Technologies, Wilmington, DE) (4.6 mm × 250 mm, 300 Å pore size). The flow rate was 1 mL/min. The mobile phase was isocratic with 90% solvent A (25 mM NH₄OAc buffer, pH = 5.0) and 10% solvent B (acetonitrile) at 0 to 2 minutes, followed by a gradient mobile phase going from 10% solvent B at 2 minutes to 15% solvent B at 5 minutes and 20% solvent B at 20 minutes.

Animal Model

Biodistribution and imaging studies were performed in compliance with the National Institutes of Health animal experimentation guidelines.⁴⁷ The protocol was approved by the Purdue University Animal Care and Use Committee. All human tumor cell lines (U87MG, MDA-MB-435, A549, HT29, and PC-3) were obtained from American Type Culture Collection (ATCC, Manassas, VA). The U87MG human glioma cells were cultured in Minimum Essential Medium Eagle (Sigma-Aldrich) with Earle's Balanced Salt Solution (nonessential amino acids sodium pyruvate; Invitrogen, Carlsbad, CA) (ATCC). PC-3 and A549 cancer cells were cultured in F-12 medium (GIBCO, Grand Island, NY). MDA-MB-435 and HT29 cancer cells were grown in RPMI 1640 medium with l-glutamine (GIBCO). All tumor cell lines were supplemented with 10% fetal bovine serum (FBS, ATCC) and 1% penicillin and streptomycin (GIBCO) solution and grown at 37°C in a humidified atmosphere of 5% CO₂ in air. Cells were grown as monolayers and were harvested or split when they reached 90% confluence to maintain exponential growth. Female athymic nu/nu mice were purchased from Harlan Laboratories (Indianapolis, IN) at 4 to 5 weeks of age and were subcutaneously implanted with 5 × 10⁶ tumor cells in 0.1 mL of saline into mammary fat pads (MDA-MB-435) or shoulder flanks (U87MG, A549, HT29, and PC-3). All procedures were performed in a laminar flow cabinet using aseptic techniques. Four to 6 weeks after inoculation, the tumor size was 0.1 to 0.5 g, and the animals were used for biodistribution and imaging studies.

Biodistribution Protocol

Three female athymic nude mice (weight 20–25 g) bearing the U87MG, MDA-MB-435, A549, HT29, or PC-3 tumor xenografts were administered with the ^99mTc radiotracer (≈2.5 μCi per mouse in 0.1 mL saline) via tail vein. Animals were sacrificed at 60 minutes postinjection. Tumors were excised, dried with absorbent tissue, weighed, and counted on a PerkinElmer Wizard −1480 automatic gamma-counter (Shelton, CT). This experiment was performed twice. The tumor uptake was calculated as a percentage of the injected dose per gram of wet tissue mass (%ID/g), and the biodistribution data were presented as the mean plus the standard deviation from six tumor-bearing animals in each group.

Planar Imaging

Planar imaging was performed using the athymic nude mice (n = 3) bearing U87MG, MDA-MB-435, A549, HT29, or PC-3 tumor xenografts. Each animal was administered with ≈300 μCi of ^99mTc radiotracer in 0.1 mL saline via tail vein injection. Animals were anesthetized with intraperitoneal injection of ketamine (80 mg/kg) and xylazine (12 mg/kg) and were then placed supine on a custom-made single-head mini gamma camera (Diagnostic Services Inc., Middlesex, NJ) equipped with a parallel-hole, low-energy, and high-resolution collimator. Anterior images were acquired at 15, 30, 60, and 120 minutes postinjection and stored digitally in a 128 × 128 matrix. The acquisition count limits were set at 300 K. After completion of imaging, animals were sacrificed by sodium pentobarbital overdose (≈200 mg/kg). The whole-body planar images were selected and reported without filtration.

Cultured Primary Tumor Cells

Tumor tissues (U87MG, MDA-MB-435, A549, HT29, or PC-3) were excised from the tumor-bearing mice and were immersed in a growth medium immediately after gamma counting. The tumor tissues were rinsed twice with the Hank's solution and dissected into small pieces with razor blades. Small tumor pieces were digested with 0.25% trypsin (1 mM ethylenediaminetetraacetic acid [EDTA], without Ca²⁺ and Mg²⁺) solution at 37°C for 30 minutes, followed by vigorous pipeting and filtration through a 40 urn mesh nylon screen. After centrifugation at 1,000 rpm for 5 minutes, the pellet was resuspended in the culture medium and incubated at 37°C in a humidified atmosphere containing 5% CO₂. The purity of tumor cells could reach ≈90% after two passages, and the third passage was used for immunostaining studies.

Cellular Immunostaining

For staining studies, the primary tumor cells (U87MG, MDA-MB-435, A549, HT29, and PC-3) were seeded into eight-well chamber slides. Cells were allowed to attach and spread for > 24 hours. The tumor cells were fixed in −20°C methanol for 5 minutes and rinsed with phosphate-buffered saline (PBS). Cells were incubated in 5% bovine serum albumin for 30 minutes to block nonspecific binding and then were added to Alexa Fluor 488–conjugated mouse antihuman integrin α_vβ₃ monoclonal antibody LM609 (1:100; Millipore, Billerica, MA) for 1 hour at room temperature or incubated with rabbit antihuman and murine integrin β₃ antibody followed by incubation with Alexa Fluor 594–conjugated goat antirabbit IgG (Santa Cruz Biotechnology, Inc., Santa Cruz, CA). After washing with PBS, the slides were mounted with 4′,6-diamidino-2-phenylindole (DAPI)-Fluoromount-G (Southern-Biotech, Birmingham, AL). The same procedure, except the primary antibody was replaced by PBS, served as the negative control. The same experiment was repeated three times independently. This procedure was also used for cellular fluorescent staining studies with the human U87MG, MDA-MB-435, A549, HT29, and PC-3 cell lines.

Tumor Tissue Immunohistochemistry

For tissue staining studies, the tumor tissues were harvested from the tumor-bearing mice and were immediately snap-frozen in the optical cutting temperature solution. Tumor tissues were then cut into slices (5 urn). After thorough drying at room temperature, the slides were fixed with ice-cold acetone for 10 minutes and dried in the air for 20 minutes at room temperature. The sections were blocked with 10% goat serum for 30 minutes at room temperature and then were incubated with the hamster anti–integrin β₃ antibody (1:100; BD Biosciences, San Jose, CA) and rat anti-CD31 antibody (1:100; BD Biosciences) for 1 hour at room temperature. After incubating with the Cy3-conjugated goat antihamster and fluorescein isothiocyanate (FITC)-conjugated goat antirat secondary antibodies (1:100; Jackson ImmunoResearch Inc., West Grove, PA) and washing with PBS, the fluorescence was visualized with a Nikon fluorescence microscope (Nikon Instruments, Melville, NY). Quantitative analysis of CD31 and the total β₃ expression levels was performed after immunostaining of the tumor tissues. All pictures were taken under 100× magnification with the same exposure time. Brightness and contrast adjustments were made equally to all images. The average area of positively stained CD31 or β₃ on cryostat sections from at least 15 randomly selected fields in each group was calculated to assess the relative expression in the tumor tissues by National Institutes of Health ImageJ software (Bethesda, MD). Experiments were repeated three times independently. The fluorescent density was expressed as a percentage of the total area and presented as the mean ± SD. The fluorescent density data were plotted against the radiotracer %ID/g uptake (radioactivity density).

Data and Statistical Analysis

Analysis of the expression of CD31 and total β₃ was derived from at least 15 different regions under 100× magnification and expressed as mean ± SD. Statistical analysis was performed by one-way analysis of variance (ANOVA) followed by the Newman-Keuls test for multiple comparisons. The level of significance was set at p < .05.

Results

Biodistribution

In this study, we used five animal models (U87MG, MDA-MB-435, A549, HT29, and PC-3) to compare the tumor uptake of three ^99mTc radiotracers. As illustrated in Figure 2, the U87MG glioma uptake was the highest (^99mTc-3P-RGD₂: 11.2 ± 1.97 %ID/g; ^99mTc-3G-RGD₂: 11.73 ± 2.2 %ID/g; and ^99mTcO(MAG₂−3G-RGD₂): 8.2 ± 1.74 %ID/g). In contrast, the PC-3 tumor uptake was the lowest (2.29 ± 0.64 %ID/g, 1.92 ± 0.17 %ID/g, 1.12 ± 0.35%ID/g for ^99mTc-3P-RGD₂, ^99mTc-3G-RGD₂, and ^99mTcO(MAG₂−3G-RGD₂), respectively). Their uptake in the xenografted MDA-MB-435, A549, and HT29 tumors was moderate and comparable at 60 minutes postinjection within the experimental error. The tumor uptake of ^99mTc-3P-RGD₂ followed a trend: U87MG (11.2 ± 1.97%ID/g) > MDA-MB-435 (6.1 ± 0.79 %ID/g) ≈ HT29 (7.3 ± 1.78 %ID/g) ≈ A549 (5.5 ± 1.46 %ID/g) >> PC-3 (2.29 ± 0.64 %ID/g). The same general trend (see Figure 2) was observed for ^99mTc-3G-RGD₂ and ^99mTcO(MAG₂−3G-RGD₂).

Planar Imaging

To further confirm the results from biodistribution studies, we obtained whole-body images of the athymic nude mice bearing U87MG, MDA-MB-435, A549, HT29, and PC-3 xenografts. Once again, the U87MG tumors had the highest activity accumulation with the best contrast (Figure 3). PC-3 tumors were not clearly visualized owing to low tumor uptake. The MDA-MB-435, A549, and HT29 tumors were also clearly visible for all three ^99mTc radiotracers. The tumor-to-background (T/B) contrast was not as good as that in the glioma-bearing animal model, but it was much better than that in the PC-3 model. The radiotracer tumor uptake followed a general trend: U87MG > MDA-MB-435 ≈ HT29 ≈ A549 > PC-3.

Integrin αvβ3 Expression Levels on Tumor Cells

To understand differences in the radiotracer tumor uptake, the integrin α_vβ₃ expression patterns were examined in the cultured primary tumor cells extracted from tumor-bearing mice. It is known that β₃ attaches to α_IIb in addition to α_v. Given that α_IIbβ₃ is exclusively expressed on activated platelets,^48,49 staining of β₃ can correlate α_vβ₃ expression in cultured primary tumor cells. Figure 4 shows the results from cellular immunostaining studies. Apparently, the integrin α_vβ₃ expression levels followed the order of U87MG > MDA-MB-435 > A549 ≈ HT29 > PC-3 (see Figure 4, left) in the cultured primary tumor cells using LM609 antibody. A similar trend was seen with the antibody against the β₃ subunit (see Figure 4, right). The same results were obtained for the human cell lines with LM609 and the antibody against the β₃ subunit (Figure S1A). Western blot data (see supplementary Figure S1B and Figure S2A) further confirmed the results from immunostaining studies. In Western blot studies, the antibody detects the total integrin β₃, including the 97, 110, and 130 kilodalton variants.⁵⁰ Integrin α_v expression was also evaluated. In all cases, PC-3 tumor cells had the lowest α_v expression level (see supplementary Figure S2A).

Figure 2.

The uptake of ^99mTc-3P-RGD₂, ^99mTc-3G-RGD₂, and ^99mTcO(MAG₂−3G-RGD₂) in athymic nude mice bearing U87MG, MDA-MB-435, A549, HT29, and PC-3 tumor xenografts (N = 6) at 60 minutes postinjection. For each group, the ^99mTc radiotracer (≈2.5 μCi in 0.1 mL saline) was administered via tail vein. The tumor uptake data are expressed as %ID/g ± SD. *p < .05, significantly different from all the other groups; ^†p < .05, significantly different from the U87MG group; ^#p < .05, significantly different from the PC3 group.

Figure 3.

The representative 60-minute whole-body planar images of the tumor-bearing mice (U87MG, MDA-MB-435, A549, HT29, and PC-3) administered with 300 μCi of ^99mTc-3P-RGD₂, ^99mTc-3G-RGD₂, and ^99mTcO(MAG₂−3G-RGD₂). Experiments were repeated three times in each group, with similar results. Arrows indicate the presence of tumors in planar images.

Integrin αvβ3 Expression Levels on Tumor Tissue

Immunohistochemistry was performed to determine the total integrin β₃ expression levels on both the tumor cells and tumor neovasculature. CD31 was used as the endothelial biomarker to assess blood vessel density. Figure 5 illustrates the microscopic fluorescence images of the xenografted tumor tissues (U87MG, MDA-MB-435, A549, HT29, and PC-3) labeled with anti–integrin β₃ (red) or anti-CD31 (green) antibody. In the overlay pictures, the green color indicates the presence of blood vessels, the red color indicates the presence of integrin β₃, and the yellow color indicates integrin β₃ expressed on neovasculature. Figure 6 shows the quantitative analysis of CD31 (see Figure 6A) and β₃ (see Figure 6B) for five different xenografted tumor tissues (U87MG, MDA-MB-435, A549, HT29, and PC-3). The total β₃ expression (tumor cells and neovasculature) was defined by the percentage of the red-colored area over the total area in each slice of tumor tissue. Blood vessel density (CD31 expression level) was quantified by measuring the percentage of the green-colored area over the total area in each tumor section slide. We found that the integrin β₃ expression level was the highest in U87MG glioma tissues and the lowest in PC3 tumor tissues. The total integrin β₃ expression levels followed the trend U87MG > MDA-MB-435 ≈ A549 ≈ HT29 > PC-3 (see Figure 6B), which is completely consistent with the ex vivo biodistribution data (see Figure 2). These results were further confirmed by the results from Western blot analysis of the tumor tissues (see supplementary Figure S2b). In contrast, the blood vessel density was very high in U87MG glioma and HT29 tumor tissues, whereas it was very low in PC-3 tumor tissues. The CD31 expression levels followed the order of U87MG ≈ HT29 > MDA-MB-435 ≈ A549 > PC-3 (see Figure 6A).

Figure 4.

Representative fluorescence microscopic images of the cultured primary tumor cells extracted from athymic nude mice bearing U87MG, MDA-MB-435, A549, HT29, and PC-3 tumor xenografts stained with anti–integrin α_vβ₃ (green) and anti-β₃ (red) antibodies. The blue color indicates the nuclei (DAPI). After fixation, cells were washed with PBS and incubated with Alexa Fluor 488–conjugated mouse antihuman α_vβ₃ monoclonal antibody LM609 for 1 hour or with rabbit antihuman and antimurine integrin β₃ antibody followed by incubation with Alexa Fluor 594–conjugated goat antirabbit IgG. Images were acquired by a Nikon digital camera (400× magnification).

Relationship between Tumor Uptake and Integrin β3 Expression Levels

Figure 7 illustrates the plots of tumor uptake (%ID/g: radioactivity density) for ^99mTc-3P-RGD₂ (top), ^99mTc-3G-RGD₂ (middle), and ^99mTcO(MAG₂−3G-RGD₂) (bottom) and the integrin β₃ expression levels (fluorescence density) in the xenografted U87MG, MDA-MB-435, A549, HT29, and PC-3 tumor tissues. Apparently, there is a linear relationship between the radiotracer %ID/g tumor uptake and the integrin β₃ expression levels, with R² being .95, .92, and 0.96, respectively.

Discussion

In this study, we evaluated ^99mTc-3P-RGD₂, ^99mTc-3G-RGD₂, and ^99mTcO(MAG₂−3G-RGD₂) as the integrin α_vβ₃–targeted radiotracers in five different tumor-bearing animal models. Biodistribution data indicate that all three ^99mTc radiotracers have the highest uptake in U87MG glioma and the lowest uptake in PC-3 tumors. The radiotracer tumor uptake followed the general trend of U87MG > MDA-MB-435 ≈ HT29 ≈ A549 > PC-3 (see Figure 2), which was further confirmed by planar imaging studies (see Figure 3). It was also found that the cultured primary U87MG tumor cells and U87MG tumor tissues had the highest integrin α_vβ₃ expression, whereas the cultured primary PC-3 tumor cells and PC-3 tumor tissues had the lowest integrin α_vβ₃ expression (see Figure 4). Western blot data (see supplementary Figure S2A) are completely consistent with the results from immunostaining studies (see Figure 4). The integrin α_vβ₃ levels on the cultured primary tumor cells followed the order of U87MG > MDA-MB-435 > HT29 ≈ A549 > PC-3, which seems inconsistent with the general trend of the radiotracer tumor uptake (see Figure 2). Thus, the contribution of the tumor neovasculature to the total integrin α_vβ₃ expression must be taken into account when comparing the radiotracer tumor uptake difference in various tumor-bearing animal models.

Integrin α_vβ₃ is overexpressed on both tumor cells and activated endothelial cells of the tumor neovasculature.^33–39 In this study, we found that the total integrin α_vβ₃ expression levels follow the order of U87MG > MDA-MB-435 ≈ A549 ≈ HT29 > PC-3 (see Figure 6B). Even though the integrin α_vβ₃ expressed on the cultured primary HT29 colon cancer cells is not as high as that on MDA-MB-435 breast cancer cells (see Figure 3), the higher blood vessel density (see Figure 6A) in HT29 colon tumor tissues compared to that on the MDA-MB-435 breast tumor tissues might explain the similar radiotracer uptake in the xenografted MDA-MB-435 and HT29 tumors (see Figure 2). On the basis of these results, we believe that the integrin α_vβ₃ expressed on both tumor cells and the neovasculature contributes to the tumor uptake of ^99mTc radiotracers.

Figure 5.

Representative microscopic fluorescence images of the xenografted tumor tissues (U87MG, MDA-MB-435, A549, HT29, and PC-3) labeled with anti–integrin β₃ (red) or anti-CD31 (green) antibody or combination of the two. Yellow color, red integrin β₃ staining merged with green CD31 staining indicates the presence of integrin β₃ on the tumor neovasculature. After fixation, the tissues were incubated with hamster anti–integrin β₃ and rat anti-CD31 antibodies for 1 hour followed by incubation with Cy3-conjugated goat antihamster and FITC-conjugated goat antirat secondary antibodies. Images were acquired by a Nikon fluorescence microscope (200× magnification).

The linear relationship (see Figure 7) between the tumor uptake (%ID/g) and integrin α_vβ₃ density strongly suggests that ^99mTc-3P-RGD₂, ^99mTc-3G-RGD₂, and ^99mTcO(MAG₂−3G-RGD₂) are useful for noninvasive monitoring of integrin α_vβ₃ expression levels in cancer patients. This conclusion is completely consistent with the results from clinical studies with [¹⁸F]galacto-RGD in cancer patients.^41–45 The ability to noninvasively quantify or estimate the integrin α_vβ₃ level provides new opportunities to select patients more appropriately for planning antiangiogenic treatment.^10–12 For example, if the patient shows significant tumor uptake of the radiotracer (PET or single-photon emission computed tomography [SPECT]) owing to high integrin α_vβ₃ expression, he or she would most likely be responsive to antiangiogenic treatment. Conversely, if the patient shows very little radiotracer tumor uptake, indicating low integrin α_vβ₃ expression, antiangiogenic therapy would not be effective regardless of the amount of antiangiogenic drug administered to the cancer patient.

The next question is how much of the contribution is from the tumor cells or the neovasculature. Based on the results from this study, we believe that the contribution from the tumor cell integrin α_vβ₃ depends largely on the tumor type. If the tumor has high levels of integrin α_vβ₃ expression on tumor cells and neovasculature (eg, U87MG glioma), the radiotracer would have high tumor uptake. Conversely, if the tumor has low integrin α_vβ₃ expression levels on tumor cells and neovasculature (eg, PC-3 prostate cancer), the radiotracer tumor uptake would be low. The xenografted U87MG and HT29 tumor tissues share a similar blood vessel density (see Figure 6A), but the radiotracer tumor uptake (see Figure 2) in U87MG glioma is significantly higher than that in HT29 tumor owing to the higher integrin α_vβ₃ levels on U87MG glioma cells (see Figure 4). Xenografted MDA-MB-435, A549, and HT29 tumors have similar integrin β₃ levels (see Figure 6B) and share almost identical tumor uptake (see Figure 3). The total integrin α_vβ₃ expression level is responsible for the α_vβ₃–targeted radiotracer tumor uptake. It must be noted that not all blood vessels in tumor tissues express integrin α_vβ₃. For example, many blood vessels have little expression of integrin β₃ in U87MG and HT29 tumor xenografts, as indicated by the green-colored area in the overlay images, whereas the majority of the blood vessels in the MDA-MB-435 and A549 tumor xenografts express integrin β₃, as indicated by the presence of more yellow-colored area. Given that integrin β₃ is expressed in tumor microvessels, not mature large blood vessels, caution must be taken when correlating the radiotracer tumor uptake and blood vessel density.

Figure 6.

Quantitative analysis of CD31 (A) and β₃ (B) immunostaining from five different xenografted tumor tissues (U87MG, MDA-MB-435, A549, HT29, and PC-3). CD31 expression is represented by the percentage of green area over the total area in each slice of tissue. The total integrin β₃ expression (tumor cells and neovasculature) is represented by the percentage of red area over the total area in each slice of tumor tissue. Each data point was derived from at least 15 different areas of the same tissue (100× magnification). Experiments were repeated three times independently with similar results. Values are means ± SD. *p < .05, significantly different from all the other groups; ^†p < .05, significantly different from the U87MG group; ^#p < .05, significantly different from the PC-3 group.

Figure 7.

Relationship between tumor uptake (%ID/g: radioactivity density) and the relative β₃ expression (% red color area over the total area in each slice of tumor tissue: fluorescence density) in five different xenografted tumors (U87MG, MDA-MB-435, A549, HT29, and PC-3).

It is important to note that the fluorescence distribution in the xenografted tumor tissues is not homogeneous. In many cases, the distribution pattern was significantly different on two tumors from the same animal or even in different areas of the same tumor tissue. In fact, the fluorescence distribution heterogeneity is characteristic of all five xenografted tumors (U87MG, MDA-MB-435, A549, HT29, and PC-3). This is also why we used the average area of positively stained β₃ and CD31 on cryostat sections from at least 15 randomly selected fields in each group to assess the fluorescence density in the tumor tissues. This may also explain why radiotracer tumor uptake values often have such a large standard deviation in bio distribution studies (see Figure 3).

There are potential limitations to this study. First, the xenografted tumor models were established by subcutaneous injection of human tumor cells. Although the tumor-bearing animal models used in this study may not be representative of the microenvironment for the growth, invasion, and metastasis of human tumors, they are good enough for us to explore the relationship between radiotracer tumor uptake and integrin α_vβ₃ expression levels. Cellular staining data with LM609 suggest that cultured tumor primary cells are able to maintain many characteristics of human cancer cells. Second, quantification of the integrin α_vβ₃ heterodimer is extremely difficult because no Western blot techniques are currently available for the combined integrin α_vβ₃ subunits. In this study, we use “fluorescent density” from immunostaining studies to correlate the radiotracer tumor uptake (radioactivity density %ID/g) because quantification of absolute fluorescent intensity is very much operator dependent and subject to individual interpretation. Considering the “uncontrolled recovery rate” of the α_v and β₃ subunits from the xenografted tumor tissues when lysing the tissues, the results of Western blot studies are used only as supplementary information. Third, tumors of different sizes might have different integrin α_vβ₃ expression patterns. The expression levels of integrin α_vβ₃ and blood vessel endothelial cell biomarker CD31 only represent the status under specific experimental conditions, which is restricted by multiple factors, including animal species and sex, inoculation location, tumor cell type and culture conditions, tumor growth time, and tumor size. For example, the PC-3 cell line is known for low expression of integrin α_vβ₃.⁵¹ However, the subcutaneous injection of PC-3 cells into the hindlimb of BALB/c nu/nu mice produced a higher level of angiogenesis.⁵² Also, the higher level of integrin α_vβ₃ expression on activated endothelial cells in the xenografted tumor generated higher uptake of the imaging agent.⁵³ The slow progression and low density of the blood vessels in the PC-3 xenografted tumor shown in this study represent the outcome under particular experimental conditions (female athymic nude mice, subcutaneous injection in the shoulder flanks, etc.). We also found that PC-3 tumors grown in male mice had properties almost identical to those in female mice. Finally, further work needs to be done in cancer patients even though the linear relationship between tumor uptake (%ID/g) and integrin α_vβ₃ expression levels has been clearly established in the tumor-bearing animal models used in this study.

Conclusions

We evaluated ^99mTc-3P-RGD₂ for its ability to image integrin α_vβ₃ expression in xenografted U87MG, MDA-MB-435, A549, HT29, and PC-3 tumors. There are several significant findings from this study. First, the ex vivo biodistribution data indicate that ^99mTc-3P-RGD₂ has the highest uptake in U87MG glioma and the lowest uptake in PC-3 tumor. Its tumor uptake value followed the general trend: U87MG > MDA-MB-435 ≈ A549 ≈ HT29 > PC-3. The same general trend was observed for ^99mTc-3G-RGD₂ and ^99mTcO(MAG₂−3G-RGD₂). Cellular and tumor tissue immunostaining studies indicate that U87MG glioma cells and U87MG glioma tissues have the highest integrin α_vβ₃ expression levels, whereas the PC-3 cells and PC-3 tumor tissues have little integrin α_vβ₃ expression. The integrin α_vβ₃ expression levels on the cultured primary tumor cells followed the order of U87MG > MDA-MB-435 > HT29 ≈ A549 > PC-3. The total integrin β₃ expression levels, as determined by tissue staining, followed the general trend: U87MG > MDA-MB-435 ≈ A549 ≈ HT29 > PC-3. There is a linear relationship between radiotracer %ID/g tumor uptake and integrin β₃ expression. Thus, we conclude that radiotracer tumor uptake is contributed by integrin α_vβ₃ expressed on both tumor cells and activated endothelial cells of the tumor neovasculature. ^99mTc-3P-RGD₂ is an excellent candidate for clinical evaluations because of its high tumor uptake, long tumor retention time, high metabolic stability, and ability to monitor integrin α_vβ₃ expression in a noninvasive fashion.

Footnotes

Acknowledgments

Financial disclosure of authors: This work was supported, in part, by Purdue University and research grants: R01 CA115883 from the National Cancer Institute and DE-FG02-08ER64684 from the Department of Energy.

Financial disclosure of reviewers: None reported.

References

Haubner

Wester

. Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr Pharm Des 2004;10:1439–55.

Chen

. Multimodality imaging of tumor integrin α_vβ₃ expression. Mini Rev Med Chem 2006;6:227–34.

Daldrup-Link

Simon

Brasch

. Imaging of tumor angiogenesis: current approaches and future prospects. Curr Pharm Des 2006;12:2661–72.

Liu

. Radiolabeled multimeric cyclic RGD peptides as integrin α_vβ₃-targeted radiotracers for tumor imaging. Mol Pharm 2006;3:472–87.

Cai

Chen

. Multimodality molecular imaging of tumor angiogenesis. J Nucl Med 2008;49:113S–28S.

Cai

Niu

Chen

. Imaging of integrins as biomarkers for tumor angiogenesis. Curr Pharm Des 2008;14:2943–73.

Chen

. Advances in anatomic, functional, and molecular imaging of angiogenesis. J Nucl Med 2008;49:511–4.

Schottelius

Laufer

Kessler

Wester

. Ligands for mapping α_vβ₃-integrin expression in vivo. Acc Chem Res 2009;42:969–80.

Liu

. Radiolabeled cyclic RGD peptides as integrin α_vβ₃–targeted radiotracers: maximizing binding affinity via bivalency. Bioconj Chem 2009;20:2199–213.

10.

Miller

Pien

Sahani

. Imaging angiogenesis: applications and potential for drug development. J Natl Cancer Inst 2005;97:172–87.

11.

Cai

Rao

Gambhir

Chen

How molecular imaging is speeding up antiangiogenic drug development. Mol Cancer Ther 2006;5:2624–33.

12.

Niu

Chen

. Has molecular and cellular imaging enhanced drug discovery and drug development? Drugs R D 2008;9:351–68.

13.

Thumshirn

Hersel

Goodman

Kessler

. Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation. Chem Eur J 2003;9:2717–25.

14.

Chen

Liu

Hou

. MicroPET imaging of breast cancer α_v-integrin expression with ⁶⁴Cu–labeled dimeric RGD peptides. Mol Imaging Biol 2004;6:350–9.

15.

Zhang

Xiong

. MicroPET imaging of glioma integrin α_vβ₃ expression using ⁶⁴Cu–labeled tetrameric RGD peptide. J Nucl Med 2005;46:1707–18.

16.

Zhang

Xiong

. Quantitative PET imaging of tumor integrin α_vβ₃ expression with ¹⁸F-FRGD2. J Nucl Med 2006;47:113–21.

17.

Chen

. Micro-PET of tumor integrin α_vβ₃ expression using ¹⁸F-labeled PEGylated tetrameric RGD peptide (¹⁸F-FPRGD4). J Nucl Med 2007;48:1536–44.

18.

Janssen

Oyen

WIG

Dijkgraaf

. Tumor targeting with radiolabeled α_vβ₃ integrin binding peptides in a nude mouse model. Cancer Res 2002;62:6146–51.

19.

Janssen

Oyen

WIG

Massuger

LFAG

. Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother Radiopharm 2002;17:641–6.

20.

Dijkgraaf

Kruijtzer

JAW

Liu

. Improved targeting of the α_vβ₃ integrin by multimerization of RGD peptides. Eur J Nucl Med Mol Imaging 2007;34:267–73.

21.

Dijkgraaf

Liu

Kruijtzer

JAW

. Effect of linker variation on the in vitro and in vivo characteristics of an ¹¹¹In-labeled RGD peptide. Nucl Med Biol 2007;34:29–35.

22.

Liu

Hsieh

Jiang

. Evaluation of a ^99mTc-labeled cyclic RGD tetramer for non-invasive imaging integrin α_vβ₃-positive breast cancer. Bioconj Chem 2007;18:438–46.

23.

Wang

Kim

Liu

. ^99mTc-labeling of HYNIC-conjugated cyclic RGDfK dimer and tetramer using EDDA as coligand. Bioconj Chem 2008;19:634–42.

24.

Chen

. ⁶⁸Ga-labeled multimeric RGD peptides for microPET imaging of integrin α_vβ₃ expression. Eur J Nucl Med Mol Imaging 2008;35:1100–8.

25.

Wang

Kim

Shi

. Improving tumor targeting capability and pharmacokinetics of ^99mTc-labeled cyclic RGD dimers with PEG₄ linkers. Mol Pharm 2009;6:231–45.

26.

Shi

Wang

Kim

. Improving tumor uptake and excretion kinetics of ^99mTc-labeled cyclic arginine-glycine-aspartic (RGD) dimers with triglycine linkers. J Med Chem 2008;51:7980–90.

27.

Shi

Wang

Kim

. Improving tumor uptake and pharmacokinetics of ⁶⁴Cu-labeled cyclic RGD dimers with triglycine and PEG₄ Linkers. Bioconj Chem 2009;20:750–9.

28.

Shi

Wang

Kim

. ^99mTcO(MAG₂−3G3-dimer): a new integrin α_vβ₃-targeted radiotracer with high tumor uptake and favorable pharmacokinetics. Eur J Nucl Med Mol Imaging 2009;36:1874–84.

29.

Shi

Kim

Chakraborty

. 2-Mercaptoacetylglycylglycyl (MAG₂) as a bifunctional chelator for ^99mTc-labeling of cyclic RGD dimers: effects of technetium chelate on tumor uptake and pharmacokinetics. Bioconj Chem 2009;20:1559–68.

30.

Liu

Jia

Shi

. Tumor uptake of the RGD dimeric probe ^99mTc-G3-2P₄-RGD₂ is correlated with integrin α_vβ₃ expressed on both tumor cells and neovasculature. Bioconj Chem 2010;21:548–55.

31.

Chakraborty

Shi

Kim

. Evaluation of ¹¹¹In-labeled cyclic RGD peptides: tetrameric not tetravalent. Bioconj Chem 2010;21:969–78.

32.

Jia

Liu

Zhou

. Blood clearance kinetics, biodistribution and radiation dosimetry of a kit-formulated integrin α_vβ₃-selective radiotracer ^99mTc-3PRGD₂ in non-human primates. Mol Imaging Biol 2010; Accepted. doi:10.1007/sll307-010-0385-y.

33.

Folkman

. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27–31.

34.

Folkman

. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29:15–18.

35.

Sengupta

Chattopadhyay

Mitra

. Role of α_vβ₃ integrin receptors in breast tumor. J Exp Clin Cancer Res 2001;20:585–90.

36.

Bögler

Mikkelsen

. Angiogenesis in glioma: molecular mechanisms and roadblocks to translation. Cancer J 2003;9:205–13.

37.

Hwang

Varner

. The role of integrins in tumor angiogenesis. Hematol Oncol Clin North Am 2004;18:991–1006.

38.

Brooks

Clark

RAF

Cheresh

. Requirement of vascular integrin α_vβ₃ for angiogenesis. Science 1994;264:569–71.

39.

Zitzmann

Ehemann

Schwab

. Arginine–glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor endothelial cells in vivo. Cancer Res 2002;62:5139–43.

40.

Horton

. The α_vβ₃ integrin “vitronectin receptor.” Int J Biochem Cell Biol 1997;29:721–5.

41.

Haubner

Weber

Beer

. Noninvasive visualization of the activated α_vβ₃ integrin in cancer patients by positron emission tomography and [¹⁸F]galacto–RGD. PLoS Med 2005;2:244–52.

42.

Beer

Haubner

Sarbia

. Positron emission tomography using [¹⁸F]galacto–RGD identifies the level of integrin α_vβ₃ expression in man. Clin Cancer Res 2006;12:3942–9.

43.

Beer

Grosu

Carlsen

. [¹⁸F]galacto–RGD positron emission tomography for imaging of α_vβ₃ expression on the neovasculature in patients with squamous cell carcinoma of the head and neck Clin Cancer Res 2007;13:6610–6.

44.

Beer

Lorenzen

Metz

. Comparison of integrin α_vβ₃ expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using ¹⁸F-galacto-RGD and ¹⁸F-FDG. J Nucl Med 2008;49:22–9.

45.

Schnell

Krebs

Carlsen

. Imaging of integrin α_vβ₃ expression in patients with malignant glioma [¹⁸F]galacto-RGD positron emission tomography. Neuro Oncol 2009;11:861–70.

46.

Zhang

Xiong

. Quantitative PET imaging of tumor integrin α_vβ₃ expression with ¹⁸F-FRGD2. J Nucl Med 2006;47:113–21.

47.

National Institues of Health. Principles of laboratory animal care. Bethesda (MD): National Institutes of Health; 1985. NIH Publication No. 86–23.

48.

Scarborough

Kleiman

Phillips

. Platelet glycoprotein Ilb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use? Circulation 1999;100:437–44.

49.

Langer

Haubner

Pichler

Gawaz

. Radionuclide imaging: a molecular key to the atherosclerotic plaque. J Am Coll Cardiol 2008;52:1–12.

50.

Kumar

James

Womg

. Cloning and characterization of a novel integrin β3 subunit. J Biol Chem 1997;272:16390–7.

51.

Chatterjee

Brite

Matsumura

. Induction of apoptosis of integrin–expressing human prostate cancer cells by cyclic Arg-Gly-Asp peptides. Clin Cancer Res 2001;7:3006–11.

52.

Abdollahi

Griggs

Zieher

. Inhibition of α_vβ₃ integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res 2005;11:6270–9.

53.

Chen

. ¹⁸F-labeled BBN-RGD heterodimer for prostate cancer imaging. J Nucl Med 2008;49:453–61.

99m Tc-Labeled Cyclic RGD Peptides for Noninvasive Monitoring of Tumor Integrin α v β 3 Expression

Abstract

Experimental

Materials and Methods

Animal Model

Biodistribution Protocol

Planar Imaging

Cultured Primary Tumor Cells

Cellular Immunostaining

Tumor Tissue Immunohistochemistry

Data and Statistical Analysis

Results

Biodistribution

Planar Imaging

Integrin αvβ3 Expression Levels on Tumor Cells

Integrin αvβ3 Expression Levels on Tumor Tissue

Relationship between Tumor Uptake and Integrin β3 Expression Levels

Discussion

Conclusions

Footnotes

Acknowledgments

References